These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 26067995)

  • 1. nab-Paclitaxel dose and schedule in breast cancer.
    Martín M
    Breast Cancer Res; 2015 Jun; 17(1):81. PubMed ID: 26067995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
    Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
    Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.
    Liang C; Li L; Fraser CD; Ko A; Corzo D; Enger C; Patt D
    BMC Cancer; 2015 Dec; 15():1019. PubMed ID: 26714468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts.
    Arpino G; Marmé F; Cortés J; Ricevuto E; Leonard R; Llombart-Cussac A
    Crit Rev Oncol Hematol; 2016 Mar; 99():81-90. PubMed ID: 26712590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
    Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
    J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
    Aapro M; Tjulandin S; Bhar P; Gradishar W
    Breast; 2011 Oct; 20(5):468-74. PubMed ID: 21843943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).
    Rugo HS; Barry WT; Moreno-Aspitia A; Lyss AP; Cirrincione C; Leung E; Mayer EL; Naughton M; Toppmeyer D; Carey LA; Perez EA; Hudis C; Winer EP
    J Clin Oncol; 2015 Jul; 33(21):2361-9. PubMed ID: 26056183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P; McGuire JR; Iglesias J
    Clin Breast Cancer; 2012 Oct; 12(5):313-21. PubMed ID: 22728026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
    Chirgwin J; Chua SL
    Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study.
    Robert N; Krekow L; Stokoe C; Clawson A; Iglesias J; O'Shaughnessy J
    Breast Cancer Res Treat; 2011 Jan; 125(1):115-20. PubMed ID: 20945091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nab-paclitaxel 125 mg/m
    Furlanetto J; Jackisch C; Untch M; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Costa SD; Gerber B; Nekljudova V; Loibl S; von Minckwitz G
    Breast Cancer Res Treat; 2017 Jun; 163(3):495-506. PubMed ID: 28315068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
    Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
    Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.
    Seidman AD; Conlin AK; Bach A; Moynahan ME; Lake D; Forero A; Wright GS; Hackney MH; Clawson A; Norton L; Hudis CA
    Clin Breast Cancer; 2013 Aug; 13(4):239-246.e1. PubMed ID: 23829890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy for breast cancer with weekly nab-paclitaxel followed by epirubicin and cyclophosphamide--results of a case series.
    Hahn A; Schlotter CM; Rossmanith WG; Ulmer HU; Staiger HJ; Villena C
    In Vivo; 2014; 28(2):235-41. PubMed ID: 24632979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 Dose-Escalation Study of Triweekly Nab-Paclitaxel Combined With S-1 for HER2-Negative Metastatic Breast Cancer.
    Morimoto M; Toba H; Aoyama M; Nakagawa M; Takechi H; Yoshida T; Tangoku A
    Clin Breast Cancer; 2020 Dec; 20(6):448-453. PubMed ID: 32800494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.